Clinical Trials

Thu, 17/09/2020 - 12:00
The Huntington Study Group (“HSG”), a world leader in clinical research for Huntington’s Disease (HD), announces a partnership with Prilenia Therapeutics, a clinical stage biotech company led by Michael R. Hayden, MD, PhD, to conduct PRidopidine Outcome On Function in Huntington’s Disease (PROOF-HD) clinical study. PROOF-HD is a global Phase 3, randomized, double-blind, placebo-controlled, parallel arm, multicenter study evaluating the efficacy and safety of pridopidine in patients with early stage HD.
Mon, 14/09/2020 - 13:00
London, UK, 14th September 2020 / Sciad Newswire / WEP Group Holdings Limited (WEP), a specialist CRO focused on delive
Tue, 21/07/2020 - 07:30
Norwich, UK, 21st July 2020 / Sciad Newswire / The Smarter Food Company has raised £1m in funding to accelerate the devel
Tue, 02/06/2020 - 06:00
Louvain-la-Neuve, Belgium, 2nd June 2020 / Sciad Newswire / 
Tue, 26/11/2019 - 07:30
London, UK, 26th November 2019 / Sciad Newswire / Prokarium, a private biotechnology company developing vaccines against
Wade Wirta
Wed, 09/10/2019 - 07:00
Louvain-la-Neuve, Belgium, 9th October 2019 / Sciad Newswire / 
Tue, 01/10/2019 - 07:00
Louvain la Neuve, Belgium, 1st October 2019 / Sciad Newswire / 
Sat, 25/05/2019 - 06:30
Potential New Treatment for Acute Heart Failure Presented at the Heart Failure 2019 Congress  TARGET-1 and TARGET-2 trials: safe decongestion using first fully automated fluid management system 
Thu, 09/05/2019 - 07:00
Cell encapsulation for transport of cells and tissues at room temperature
Tue, 12/03/2019 - 07:00
Unique management tool for minimizing costs, drug waste and risk

Pages